Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016

1 of 3
Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016

Summary

‘Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016’, provides an overview of the Takeda Pharmaceutical Company Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Takeda Pharmaceutical Company Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Takeda Pharmaceutical Company Limited
- The report provides overview of Takeda Pharmaceutical Company Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Takeda Pharmaceutical Company Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Takeda Pharmaceutical Company Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Takeda Pharmaceutical Company Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Takeda Pharmaceutical Company Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Takeda Pharmaceutical Company Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

Takeda Pharmaceutical Company Limited Snapshot

Takeda Pharmaceutical Company Limited Overview

Key Information

Key Facts

Takeda Pharmaceutical Company Limited - Research and Development Overview

Key Therapeutic Areas

Takeda Pharmaceutical Company Limited - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Takeda Pharmaceutical Company Limited - Pipeline Products Glance

Takeda Pharmaceutical Company Limited - Late Stage Pipeline Products

Takeda Pharmaceutical Company Limited - Clinical Stage Pipeline Products

Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products

Takeda Pharmaceutical Company Limited - Drug Profiles

(alogliptin benzoate + metformin hydrochloride)

(alogliptin benzoate + pioglitazone hydrochloride)

brentuximab vedotin

ceftaroline fosamil

ixazomib citrate

ramelteon

vedolizumab

roflumilast

(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide)

azilsartan medoxomil

febuxostat XR

immune globulin (human)

pioglitazone hydrochloride

rasagiline mesylate

relugolix

TAK-003

vortioxetine hydrobromide

AM-4

DSM-265

namilumab

TAK-063

TAK-214

TAK-272

TAK-850

J-591

TAK-020

TAK-021

TAK-058

TAK-071

TAK-079

TAK-653

TAK-792

TAK-828

TAK-831

TAK-915

TAK-935

trelagliptin succinate

(plague + small pox) vaccine

BTZO-2

chikungunya vaccine

ELQ-300

influenza [strain A/H5N1] vaccine

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine

mapatumumab

Monoclonal Antibody Conjugate to Target c-Ret for Breast Cancer

Monoclonal Antibody Conjugate to Target Guanylyl Cyclase C for Oncology

Monoclonal Antibody Conjugates for Oncology

respiratory syncytial virus (virus like particle) vaccine

Rotavirus (virus like particle) vaccine

Small Molecule 1 to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression

Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease

Small Molecule to Activate Glucokinase for Type 2 Diabetes

Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain

Small Molecule to Agonize GPR52 for Psychiatry Disorders

Small Molecule to Antagonize Androgen Receptor for Prostate Cancer

Small Molecule to Antagonize CRF1 for CNS Disorders

Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia

Small Molecule to Antagonize MCHR1 for Obesity

Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension

Small Molecule to Antagonize PDGFR and VEGFR-2 for Oncology

Small Molecule to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression

Small Molecule to Inhibit FAAH for Pain

Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease

Small Molecule to Inhibit HER2/EGFR for Oncology

Small Molecule to Inhibit NET for Stress Urinary Incontinence

Small Molecule to Inhibit PKC-Theta

Small Molecules for Parkinson's Disease

Small Molecules for Visceral Leishmaniasis

Small Molecules to Agonize GPR119 for Type II Diabetes

Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity

Small Molecules to Inhibit B-Raf for Oncology

Small Molecules to Inhibit CENP-E for Colon Cancer

Small Molecules to Inhibit DPP-IV for Type 2 Diabetes

Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma

Small Molecules to Inhibit MAP2 for Obesity

Small Molecules to Inhibit MGAT2 for Metabolic Disorders

Small Molecules to Inhibit MMP-13 for Osteoarthritis

Small Molecules to Inhibit PARP-1 for Colon Cancer

Small Molecules to Inhibit TYK2

Stem Cell Therapy for Muscular Dystrophy

T-1840383

T-3256336

TAK-041

TAK-480

TAK-632

Y-443

Small Molecule for Undisclosed Indication

Small Molecule to Inhibit Arginine Methyltrasferase for Oncology

Small Molecule to Inhibit HDAC6

Small molecules for Leishmaniasis and Trypanosomiasis

Small Molecules for Malaria

Small Molecules for Tuberculosis

Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1

Small Molecules to Inhibit FAK for Oncology

Small Molecules to Inhibit HER2 and EGFR for Oncology

Small Molecules to Inhibit IAP for Oncology

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology

Y-142

Takeda Pharmaceutical Company Limited - Pipeline Analysis

Takeda Pharmaceutical Company Limited - Pipeline Products by Target

Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration

Takeda Pharmaceutical Company Limited - Pipeline Products by Molecule Type

Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action

Takeda Pharmaceutical Company Limited - Recent Pipeline Updates

Takeda Pharmaceutical Company Limited - Dormant Projects

Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Takeda Pharmaceutical Company Limited - Company Statement

Takeda Pharmaceutical Company Limited - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 258List of Tables

Takeda Pharmaceutical Company Limited, Key Information

Takeda Pharmaceutical Company Limited, Key Facts

Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2016

Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2016

Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2016

Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2016

Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2016

Takeda Pharmaceutical Company Limited - Partnered Products/ Combination Treatment Modalities, 2016

Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2016

Takeda Pharmaceutical Company Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016

Takeda Pharmaceutical Company Limited - Pre-Registration, 2016

Takeda Pharmaceutical Company Limited - Filing rejected/Withdrawn, 2016

Takeda Pharmaceutical Company Limited - Phase III, 2016

Takeda Pharmaceutical Company Limited - Phase II, 2016

Takeda Pharmaceutical Company Limited - Phase I, 2016

Takeda Pharmaceutical Company Limited - Phase 0, 2016

Takeda Pharmaceutical Company Limited - IND/CTA Filed, 2016

Takeda Pharmaceutical Company Limited - Preclinical, 2016

Takeda Pharmaceutical Company Limited - Discovery, 2016

Takeda Pharmaceutical Company Limited - Pipeline by Target, 2016

Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2016

Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2016

Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action, 2016

Takeda Pharmaceutical Company Limited - Recent Pipeline Updates, 2016

Takeda Pharmaceutical Company Limited - Dormant Developmental Projects,2016

Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products, 2016

Takeda Pharmaceutical Company Limited, Other Locations

Takeda Pharmaceutical Company Limited, Subsidiaries 255List of Figures

Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Indication, 2016

Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2016

Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2016

Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2016

Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2016

Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2016

Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Target, 2016

Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2016

Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2016

Takeda Pharmaceutical Company Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll